Boston Scientific Corporation reported a significant increase in its financial performance for the second quarter and first half of 2026, as detailed in its latest 10-Q filing. The company achieved net sales of $5.442 billion for the quarter, marking a 7.5% increase from $5.061 billion in the same period last year. For the first six months, net sales rose to $10.646 billion, up 9.5% from $9.724 billion in 2025. The net income attributable to common stockholders also saw a notable rise, reaching $907 million in Q2 2026, a 13.8% increase from $797 million in Q2 2025, and $2.247 billion for the first half, up 52.8% from $1.471 billion.
The company attributed its growth to strong performance in its Interventional Cardiology and Vascular Therapies, as well as Electrophysiology business units. Gross profit for the second quarter was $3.848 billion, representing a gross margin of 70.7%, compared to 67.7% in the prior year. This improvement was driven by increased sales of higher-margin products and a recovery of previously incurred tariffs. Operating income for the quarter was reported at $1.178 billion, up from $819 million in Q2 2025.
Strategically, Boston Scientific has been active in expanding its portfolio through acquisitions. The company announced its intent to acquire Penumbra, Inc. for approximately $14.5 billion, which is expected to close in the second half of 2026, pending regulatory approvals. Additionally, Boston Scientific completed the acquisition of Nalu Medical, Inc. for $523 million earlier in 2026, enhancing its Neuromodulation division. The company also entered into an investment agreement with MiRus LLC, committing $1.5 billion to support the development of novel biomaterials and implants.
Operationally, Boston Scientific reported a total employee headcount of 42,000 as of June 30, 2026, reflecting its ongoing commitment to growth and innovation. The company has also initiated a new global restructuring program aimed at optimizing its supply chain and organizational structure, which is expected to result in pre-tax charges of approximately $700 million to $800 million. The restructuring is anticipated to yield annual savings of around $500 million, with a significant portion reinvested into strategic growth initiatives.
Looking ahead, Boston Scientific remains optimistic about its growth trajectory, supported by its strong financial performance and strategic investments. The company expects to continue leveraging its innovative product offerings to meet patient needs while navigating macroeconomic challenges, including potential supply chain disruptions and regulatory changes.
About BOSTON SCIENTIFIC CORP
Boston Scientific Corporation develops, manufactures, and markets medical devices across interventional medical specialties, focusing on less-invasive treatments. Its core segments include MedSurg (endoscopy, urology, neuromodulation) and Cardiovascular (cardiology, cardiac rhythm management, electrophysiology, peripheral interventions). Serving hospitals and healthcare providers globally, Boston Scientific offers innovative technologies that improve patient outcomes, reduce healthcare costs, and enhance procedural efficiency through a broad portfolio of proprietary devices and solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov